Evidence map›Paper›PMID 39472983›Full record

ArticleAlzheimer's research & therapy2024

Assessing the metabolism of the olfactory circuit by use of

Daniël S L Loewenstein, Max van Grinsven, Cécile de Pont, Paul L J Dautzenberg, Astrid M van Strien, Dylan Henssen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Eagle eyes on the human brain and beyond: PET at ultra-high spatial resolution.European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniël S L LoewensteinDepartment of Medical Imaging, Radboud University Medical Center, Geert Grooteplein Zuid 10, Nijmegen, 6525 EZ, The Netherlands. daniel.loewenstein@radboudumc.nl.
Max van GrinsvenDepartment of Medical Imaging, Radboud University Medical Center, Geert Grooteplein Zuid 10, Nijmegen, 6525 EZ, The Netherlands.
Cécile de PontDepartment of Medical Imaging, Jeroen Bosch Hospital, 's Hertogenbosch, The Netherlands.
Paul L J DautzenbergDepartment of Geriatrics, Jeroen Bosch Hospital, 's Hertogenbosch, The Netherlands.
Astrid M van StrienDepartment of Geriatrics, Jeroen Bosch Hospital, 's Hertogenbosch, The Netherlands.
Dylan HenssenDepartment of Medical Imaging, Radboud University Medical Center, Geert Grooteplein Zuid 10, Nijmegen, 6525 EZ, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe loss of olfactory function is known to occur in patients suffering from (behavioral variant) frontotemporal dementia ((bv)FTD) and Alzheimer's disease (AD), although different pathophysiological mechanisms underpin this clinical symptom in both disorders. This study assessed whether brain metabolism of the olfactory circuit as assessed by positron emission tomography (PET) imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose ([

methodsPatients presenting with cognitive decline were included from a prospectively kept database: (1) bvFTD patients, (2) AD patients and (3) patients with logopenic primary progressive aphasia (PPA). Metabolic rates were calculated for different regions of the olfactory circuit for each subgroup and compared with a cohort of subjects with normal brain metabolism. Additionally, in patients with a logopenic PPA pattern on PET-imaging, statistical parametric mapping (SPM) analysis was performed.

resultsThe metabolism of subdivisions of the olfactory circuit as assessed by [

conclusionMetabolic dysfunction in the olfactory circuit is different in various neurodegenerative disorders. Further investigation of the correlations between the cerebral metabolism and the mechanisms which drive olfactory dysfunction is needed.

Indexed as

Alzheimer DiseaseFluorodeoxyglucose F18Frontotemporal DementiaPositron Emission Tomography Computed TomographyAgedBrainFemaleHumansMaleMiddle AgedOlfactory PathwaysProspective StudiesRadiopharmaceuticalsFluorodeoxyglucose F18RadiopharmaceuticalsAlzheimer’s diseaseFDG PETFrontotemporal dementiaNeurodegenerative disordersNeuroimagingOlfactory system

Identifiers

PMID39472983
PMCPMC11520854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.